Success Metrics

Clinical Success Rate
94.4%

Based on 17 completed trials

Completion Rate
94%(17/18)
Active Trials
1(5%)
Results Posted
59%(10 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
7
35%
Ph phase_4
1
5%
Ph phase_3
3
15%
Ph phase_1
9
45%

Phase Distribution

9

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution20 total trials
Phase 1Safety & dosage
9(45.0%)
Phase 2Efficacy & side effects
7(35.0%)
Phase 3Large-scale testing
3(15.0%)
Phase 4Post-market surveillance
1(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.4%

17 of 18 finished

Non-Completion Rate

5.6%

1 ended early

Currently Active

1

trials recruiting

Total Trials

20

all time

Status Distribution
Active(1)
Completed(17)
Terminated(1)
Other(1)

Detailed Status

Completed17
Suspended1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
1
Success Rate
94.4%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (45.0%)
Phase 27 (35.0%)
Phase 33 (15.0%)
Phase 41 (5.0%)

Trials by Status

completed1785%
suspended15%
terminated15%
recruiting15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT04520178Phase 2

Effects of 5HTP on the Injured Human Spinal Cord

Recruiting
NCT04325503Phase 1

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Completed
NCT01323374Phase 2

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

Completed
NCT04000919Phase 2

Effects of 5HTP and LDOPA on CNS Excitability After SCI

Suspended
NCT00685919Phase 2

Peripheral Dopamine in Postural Tachycardia Syndrome

Completed
NCT03055936Phase 1

Dose-finding Pharmacokinetic Study in Healthy Males

Completed
NCT03266965Phase 1

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

Completed
NCT03115827Phase 4

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

Completed
NCT01399905Phase 2

High and Low Dose Carbidopa Treatment of Parkinson's Disease

Completed
NCT00845000Phase 1

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Completed
NCT00223717Phase 1

Treatment of Supine Hypertension in Autonomic Failure

Completed
NCT02633839Phase 1

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Completed
NCT02633007Phase 1

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

Completed
NCT01212484Phase 3

Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia

Completed
NCT00218075Phase 2

Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence

Completed
NCT01227655Phase 3

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.

Completed
NCT01568073Phase 3

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Completed
NCT00547911Phase 1

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Terminated
NCT01229332Phase 1

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

Completed
NCT01296464Phase 2

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20